| Title |
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, February 2012
|
| DOI | 10.2147/cpaa.s27822 |
| Pubmed ID | |
| Authors |
Rolf P Kreutz, Perry Nystrom, Yvonne Kreutz, Jia Miao, Zeruesenay Desta, Jeffrey A Breall, Lang Li, ChienWei Chiang, Richard Kovacs, David A Flockhart, Yan Jin |
| Abstract |
The metabolic activation of clopidogrel is a two-step process. It has been suggested that paraoxonase-1 (PON1) is a rate-limiting enzyme in the conversion of 2-oxo- clopidogrel to an active thiol metabolite. Conflicting results have been reported in regard to (1) the association of a common polymorphism of PON1 (Q192R) with reduced rates of coronary stent thrombosis in patients taking clopidogrel and (2) its effects on platelet inhibition in patient populations of European descent. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| China | 1 | 5% |
| Canada | 1 | 5% |
| Unknown | 17 | 89% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 16% |
| Student > Postgraduate | 3 | 16% |
| Student > Doctoral Student | 2 | 11% |
| Professor | 2 | 11% |
| Student > Ph. D. Student | 2 | 11% |
| Other | 6 | 32% |
| Unknown | 1 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 42% |
| Agricultural and Biological Sciences | 5 | 26% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Computer Science | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 3 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2012.
All research outputs
#17,438,425
of 25,584,565 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#115
of 179 outputs
Outputs of similar age
#173,824
of 254,308 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#3
of 5 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,308 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.